Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer

  title={Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer},
  author={Kristell L.S. Chatalic and Gerben M. Franssen and W. M. van Weerden and William J. Mcbride and Peter Laverman and Erik de Blois and Bouchra Hajjaj and Luc Brunel and David M. Goldenberg and Jean-Alain Fehrentz and J. Martinez and Otto C Boerman and Marion de Jong},
  journal={The Journal of Nuclear Medicine},
  pages={2050 - 2056}
Gastrin-releasing peptide receptor (GRPR) is overexpressed in human prostate cancer and is being used as a target for molecular imaging. In this study, we report on the direct comparison of 3 novel GRPR-targeted radiolabeled tracers: Al18F-JMV5132, 68Ga-JMV5132, and 68Ga-JMV4168 (JMV5132 is NODA-MPAA-βAla-βAla-[H-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], JMV4168 is DOTA-βAla-βAla-[H-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], and NODA-MPAA is 2-[4-(carboxymethyl)-7-{[4-(carboxymethyl)phenyl… 

Figures from this paper

Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical

Data related to acetate buffer, mouse, canine, and human sera stability of 177Lu-labeled RM1 are presented, suggesting that an antagonist is a more promising candidate than agonist for the positron emission tomography (PET) imaging and therapy of prostate cancer patients.

Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.

A novel bombesin analogue based on JMV594 peptide modified with an 8-amino octanoic acid spacer was designed and conjugated with the metal chelator NODAGA-SCH1 and showed promising in vivo properties and is a promising candidate for translation into clinical PET-imaging of PCa patients.

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies

This data shows that co-injection of the enzyme inhibitor PA greatly enhances the theranostic potential of GRPR-radioantagonists for future application in PCa patients.

A new class of radiopeptides for PET imaging of neuromedin-B receptor: 68Ga-ranatensin analogs

A novel class of radiopeptide analogue which potentially could be used for NMB-R molecular imaging is developed and demonstrated rapid blood and urinary clearances and uptake in the pancreas and kidneys in normal mice.

Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel-Chelator Complex on Biodistribution and Tumor Uptake.

With improved target-to-background contrast, Ga-Z02176 and (18)F-Z04139 are promising for imaging B1R expression in cancers with PET.

Preparation and Evaluation of [18F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [68Ga]Ga-DOTA/NOTA-NOC

[18F]AlF demonstrates promise as a surrogate pseudo-radiometal to gallium-68, making it possible to detect liver metastases and surpassed the other clinically well-established radiotracers in vivo, especially at 3 h p.i.

Imaging the expression of glypican-3 in hepatocellular carcinoma by PET

It is demonstrated that FAM and the 18F-labeled L5 peptide can selectively target HCC with a high expression of GPC3 in vitro and in vivo.

18F-AlF–Labeled Biomolecule Conjugates as Imaging Pharmaceuticals

  • Krishan Kumar
  • Biology, Chemistry
    The Journal of Nuclear Medicine
  • 2018
Despite the requirement of a cyclotron for 18F production, the 18F-AlF is a convenient substitute for 68Ga because of the shorter half-life and nonideal energies of 68Ga and the long lead time for availability and high cost of 68Ge/68Ga.

Diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) positron emission tomography/computed tomography in patients with brain gliomas: study protocol for an open-label single-arm clinical trial

Diagnostic performance and safety assessment of 68Ga-NOTA-Aca-BBN(7-14) in brain gliomas will provide new insights into the specific PET/CT diagnosis of braingliomas.

18F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography Imaging Pharmaceuticals.

An overview of the 18F radiochemistry and 18F-labeling methodologies for small molecules and target-specific biomolecules is provided, a comprehensive review of coordination chemistry of Al3+,18F-AlF labeling of peptide and protein conjugates, and evaluation of 18f-labeled biomolecule conjugate as potential imaging pharmaceuticals are evaluated.



Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors

The promising preclinical results warrant clinical translation of these probes for SPECT and PET of GRPr-positive tumors, and the chelators do influence the affinity, antagonistic potency, and pharmacokinetics of the conjugates.

PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an 18F-Labeled Bombesin Analog

A NotA-conjugated bombesin derivative, NOTA-8-Aoc-BBN(7-14)NH2, could be labeled rapidly and efficiently with 18F using a 1-pot, 1-step method and demonstrated GRPR-binding specificity, which was demonstrated by reduced tumor uptake of radiolabeled NOTA.

In Vitro and In Vivo Evaluation of a 18F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

The initial biological results suggest that [18F]AlF-NOTA-P2-RM26 is a promising candidate for PET imaging of GRPR in vivo.

Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.

The antagonistic bombesin analog NOTA-PEG2-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (NOTA- P2-RM26) is a promisindg candidate for prostate cancer imaging using PET and SPECT/CT.

In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548

BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer and has a sensitivity, specificity, and accuracy of 88, 81, and 83%, respectively, for detection of primary PCa and sensitivity for metastatic lymph nodes using histology as gold standard.

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer

The high-stability, efficient tumor uptake and optimal pharmacokinetic properties highlight 18F-AlF-NODAGA-RM1 as a probe with great potential and clinical application for the PET imaging of prostate cancer.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

Somatostatin antagonist radiotracers are preferable over agonists for the in vivo targeting of sst3- or sst2-expressing tumors, and antagonists for other peptide receptors need to be evaluated in nuclear oncology as a result of this paradigm shift.

Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profile.

Novel bombesin (BBN) antagonists were synthesized by coupling the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to H-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (JMV594)

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours

A new conjugate, RM2, with the chelator DOTA coupled to D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 via the cationic spacer 4-amino-1-carboxymethyl-piperidine is described for labelling with radiometals such as 111In and 68Ga.

New lyophilized kit for rapid radiofluorination of peptides.

It is indicated that (18)F-labeled peptides can be reproducibly prepared as stable Al-F complexes with good radiochemical yield and high specific activity using a simple, one-step, lyophilized kit followed by a rapid purification by SPE that provides the (18]F-peptide ready for patient injection within 30 min.